NASDAQ:KZRKezar Life Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kezar Life Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.11 -0.39 (-7.09 %) (As of 07/10/2020 04:00 PM ET) Add Compare Share Today's Range$5.09Now: $5.11▼$5.6450-Day Range$4.47MA: $5.43▼$7.7552-Week Range$2.18Now: $5.11▼$9.79Volume428,500 shsAverage Volume560,480 shsMarket Capitalization$195.08 millionP/E RatioN/ADividend YieldN/ABeta0.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis. The company was founded in 2015 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Kezar Life Sciences has a potential upside of 193.5% from its current price of $5.11.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesKezar Life Sciences has received 105 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKezar Life Sciences has received 147 “underperform” votes. (Add your “underperform” vote.)Community SentimentKezar Life Sciences has received 58.33% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote “Outperform” if you believe KZR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $8,483,998.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.60% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions48.45% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.13) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZR Previous Symbol CUSIPN/A CIKN/A Webwww.kezarlifesciences.com Phone650-822-5600Debt Debt-to-Equity Ratio0.04 Current Ratio18.69 Quick Ratio18.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book1.25Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-35,090,000.00 Net MarginsN/A Return on Equity-39.24% Return on Assets-35.09%Miscellaneous Employees24 Outstanding Shares38,177,000Market Cap$195.08 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:KZR Rates by TradingView Receive KZR News and Ratings via Email Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions How has Kezar Life Sciences' stock been impacted by COVID-19 (Coronavirus)? Kezar Life Sciences' stock was trading at $3.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KZR shares have increased by 28.1% and is now trading at $5.11. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kezar Life Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kezar Life Sciences. When is Kezar Life Sciences' next earnings date? Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Kezar Life Sciences. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences Inc (NASDAQ:KZR) released its earnings results on Thursday, May, 7th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.07. View Kezar Life Sciences' earnings history. What price target have analysts set for KZR? 4 brokers have issued twelve-month target prices for Kezar Life Sciences' stock. Their forecasts range from $12.00 to $18.00. On average, they expect Kezar Life Sciences' share price to reach $15.00 in the next twelve months. This suggests a possible upside of 193.5% from the stock's current price. View analysts' price targets for Kezar Life Sciences. Has Kezar Life Sciences been receiving favorable news coverage? News coverage about KZR stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kezar Life Sciences earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Kezar Life Sciences. Who are some of Kezar Life Sciences' key competitors? Some companies that are related to Kezar Life Sciences include Morphic (MORF), Endo International (ENDP), Kadmon (KDMN), Stoke Therapeutics (STOK), Omeros (OMER), Legend Biotech (AMTI), Applied Therapeutics (APLT), Frequency Therapeutics (FREQ), Passage Bio (ORIC), Homology Medicines (FIXX), Aprea Therapeutics (APRE), ZIOPHARM Oncology (ZIOP), Cue Biopharma (CUE), Passage Bio (KROS) and RAPT Therapeutics (RAPT). View all competitors. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Opko Health (OPK), Gilead Sciences (GILD), ADMA Biologics (ADMA), Agile Therapeutics (AGRX), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Aptinyx (APTX), Clovis Oncology (CLVS) and Crispr Therapeutics (CRSP). Who are Kezar Life Sciences' key executives? Kezar Life Sciences' management team includes the following people: Mr. John Fowler, Co-Founder, CEO & Director (Age 47)Dr. Christopher J. Kirk, Co-Founder, Pres, Chief Scientific Officer & Director (Age 47)Dr. Jack Taunton, Co-FounderMr. Marc L. Belsky, CFO & Sec. (Age 64)Michael Wolfe, Director of Fin. & Operations When did Kezar Life Sciences IPO? (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO. What is Kezar Life Sciences' stock symbol? Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR." How do I buy shares of Kezar Life Sciences? Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kezar Life Sciences' stock price today? One share of KZR stock can currently be purchased for approximately $5.11. How big of a company is Kezar Life Sciences? Kezar Life Sciences has a market capitalization of $195.08 million. The company earns $-35,090,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe. What is Kezar Life Sciences' official website? The official website for Kezar Life Sciences is www.kezarlifesciences.com. How can I contact Kezar Life Sciences? Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected] This page was last updated on 7/11/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
